Neuroinflammation and Aβ Accumulation Linked To Systemic Inflammation Are Decreased By Genetic PKR Down-Regulation

Anne-Sophie Carret-Rebillat1, Clarisse Pace1, Sarah Gourmaud1, Laura Ravasi2, Samantha Montagne-Stora1, Sophie Longueville3, Marion Tible1, Erika Sudol1, Raymond Chuen-Chung Chang4, Claire Paquet1,5, François Mouton-Liger1* & Jacques Hugon1,5*

1Inserm UMR-S942, Lariboisière Hospital, Paris, France, 2In vivo preclinical imaging facility, IFR 114 - University of Lille, Nord of France, CHU Lille, France, 3Inserm UMR-S839 Institut du Fer à Moulin and Inserm UMR932, Paris, France, 4Laboratory of Neurodegenerative Diseases, Department of Anatomy, IKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, 5Memory Center, and Department of Histology, Lariboisière Hospital, University of Paris Diderot, AP-HP, Paris, France.

Alzheimer’s disease (AD) is a neurodegenerative disorder marked by memory disturbances progressively associated with aphasia, apraxia, agnosia and behavioral symptoms. Currently, there is no cure for the disease and symptomatic treatment includes choline esterase inhibitors and glutamate antagonists. AD is neuropathologically characterized by senile plaques made of the accumulation of Aβ-peptides, neurofibrillary tangles formed by hyperphosphorylated tau protein, synaptic and neuronal losses and neuroinflammation including the presence of activated microglia1. The cause of the disease is not known but according to the amyloid cascade hypothesis, the toxicity of Aβ or Aβ oligomers could lead to detrimental consequences for neurons and to neuroinflammation2.

Brain inflammation is a key component of the pathological lesions detected in the brain of patients suffering from AD3,4. Astrocytic and microglial cell reactions are often detected surrounding senile plaques. It has been postulated that neuroinflammation could exacerbate brain lesions leading to synaptic dysfunctions and neuronal degeneration. The Aβ-peptide can trigger microglial cell activation inducing the release of the pro-inflammatory cytokines such as TNFα or IL1-β3.

Recent works have suggested that systemic inflammation could exacerbate or even drive neuronal dysfunction associated with dementia and that the kinases PKR and JNK could play a role in these molecular events4. Common molecular pathways linking Diabetes Mellitus and AD were recently proposed: mild systemic inflammation could trigger abnormal consequences in the brain including impaired neuronal insulin signalling, synapse degradation and memory disturbances associated with the release of TNFα and IL1-β. Systemic inflammation is also known to modify microglial phenotypes and systemic manipulations of inflammation can improve the
disease status by negatively alter this progression. This hypothesis stimulated our interest in determining if pro-inflammatory factors such as the ubiquitous kinase PKR, acting peripherally and in the brain, could contribute to abnormal molecular signals leading to increased neuroinflammation and AD brain lesions during systemic inflammation.

PKR is a pro-apoptotic kinase that controls the initial step of protein translation through the phosphorylation of the eukaryotic initiation factor 2 alpha (eIF2α)8. PKR is involved in several cellular pathways including innate immunity and defence against viruses. PKR can sequentially induced cell survival and death pathways. PKR also modulates the synthesis of pro-inflammatory factors via the activation of the NF-κB (nuclear factor k light-chain-enhancer of activated B cells) pathway after direct interaction with IκB (inhibitor of nuclear factor kappa-B kinase subunit beta)10. The PKR inhibitor C16 can prevent IL-1β and neuronal apoptosis induced by quinolinic acid administration11. PKR is also involved in the control of the inflammasome and HMGB1 (high-mobility group protein B1) release12. This kinase is highly expressed in degenerative neurons in AD brains and can be activated in primary neuronal cultures by Aβ13,14. In addition the levels of phosphorylated PKR are highly increased in the cerebrospinal fluid (CSF) of patients suffering from AD or Mild Cognitive Impairment15 and can correlate with the cognitive decline in AD patients16.

Since PKR is elevated in AD CSF and brains and can modulate neuroinflammatory signals, we sought to determine if PKR could control brain inflammation and Aβ accumulation after systemic LPS administration in wild-type (WT) mice and PKR−/− mice. Previous studies reported neuroinflammation induction and Aβ− increase after systemic LPS administration17. By use of this experimental model, we further investigated whether PKR played a role in triggering the molecular pathways leading to these pathological processes. The results show that PKR genetic down-regulation reduces neuroinflammation and Aβ accumulation.

Results
Systemic injection of LPS induces brain PKR phosphorylation. To assess the consequences of repeated LPS injections on PKR activation, we first performed immunofluorescence analyses of pPKR staining in sagittal slices of WT mice brain exposed to saline or LPS. In WT mice treated with saline solution, we observed a weak cytoplasmic pPKRThr446 staining in hippocampus and cortex (Figure 1A–B). Repeated injections of LPS lead to a dramatic increase of number of pPKRThr446 positive cells (Figure 1C) in both hippocampus and cortex of WT mice. We found a similar increase in hippocampus by evaluating with imageJ software the intensity of staining (Figure 1D). To evaluate the potential pro-apoptotic effects of PKR in this neuroinflammatory model, we have measured by immunoblotting the cleavage by caspase-3 of the nuclear enzyme poly ADP-ribose polymerase (PARP). LPS-induced PKR activation did not lead to a cleavage of PARP protein (Supplementary Figure 1).

PKR down-regulation prevents hippocampal LPS-induced microglial activation and cytokines production. Microglia and astrocytes are known to be major sources of neuro-inflammation and are strongly activated by intra-peritoneal LPS injection. Our immunohistofluorescence using a specific marker of microglial cells activation, IBA1 (ionized calcium-binding adaptor molecule 1) confirmed this finding (Figure 2A). Quantified immunofluorescence analyses of IBA1 positive microglia in the hippocampus, using ImageJ software, revealed a 64% increase of the staining intensity in LPS-treated mice compared to untreated mice (Figure 2B). Next, we sought to understand the role of activated PKR in neuroinflammation by injecting LPS in PKR knock-down mice (PKR−/−). PKR−/− mice did not express the functional 69 kDa protein but only at very low level a truncated product of translation (42 kDa) of PKR mRNA devoid of exons 2 and 3 (Supplementary Figure 2).

Analyses of IBA1 staining in hippocampus of LPS-treated PKR−/− mice revealed a significant decrease of microglial activation (−43%) compared to LPS-treated WT mice (Figure 2B). Similar variations were found on astrocytes activation, quantified by enumerating GFAP (glial fibrillary acidic protein)-positive cells in hippocampus (Supplementary Figure 2). Finally, we assessed hippocampal cyto-kine TNF-α mRNA level by quantitative real time PCR. As expected, the mRNAs level of TNF-α is dramatically increased in LPS-treated mice (+ 890%). In PKR−/− mice, LPS-induced TNF-α appears less overexpressed (+ 99%) (Figure 2C). In addition using Elisa, we also found that PKR down regulation abolished the increase of brain IL-6 levels induced by systemic LPS injection (Figure 2D).

BACE1 upregulation and Aβ production induced by intra-peritoneal LPS injection is reversed in PKR−/− mice. Intraperitoneal LPS administration is known to induce a brain Aβ accumulation in WT mice. To confirm this previous observation in our specific model of repeated LPS injection, we first assessed hippocampal APP processing by immunoblotting analyses of mature BACE1 (Figure 3A–B) and APP proteins (Figure 3A and C) and then by evaluating soluble Aβ levels with a specific Elisa assay (Figure 3D). Our results are consistent with observations obtained in other LPS models, with a significant increase of mature BACE1 protein level (+ 58%) and Aβ production (+ 184%). By contrast, there were no changes in APP protein. To test whether upregulation of BACE1 levels by neuroinflammation occurs only at a translational level, we measured mRNA levels of BACE1 by real-time quantitative PCR. Levels of BACE1 messengers from LPS-treated WT mice were 1.8 fold higher than those of untreated-WT mice (Figure 3E). Interestingly, LPS-treated PKR−/− mice exhibit significantly reduced levels of soluble Aβ and of BACE1 mRNA and protein compared to LPS-treated WT.

As PKR activation could also trigger tau phosphorylation in stress conditions through glycogen synthase kinase -3β (GSK3-β) phosphorylation on tyrosine 216 (pGSK3-β), we performed immunoblot analysis of pGSK3-β, GSK3-β total protein, tau total protein and phosphorylated tau on different sites, such as AT180 (supplementary Figure 4A). Our results reveal a significant increase of pGSK3-β/GSK3-β ratios (+ 34%) (Supplementary Figure 4B) which is not associated with an increase of tau phosphorylation on AT180 (supplementary Figure 4C), AT8 or AT270 (not shown).

Increase of activated STAT3 level by systemic LPS administration is PKR dependent. Previous in vitro researches have shown that stress-induced eIF2α phosphorylation at serine 52 by PKR could increase BACE1 translation and lead to Aβ over-production. Immunoblotting for phosphorylated eIF2α (p-eIF2α) and eIF2α total protein (Figure 4A) enabled the assessment of the role of the eIF2α activation in LPS-induced amyloidogenic signaling. It showed that p-eIF2αSer52/eIF2α ratio is not affected by systemic LPS administration (Figure 4B), suggesting an alternative PKR-dependent pathway for BACE1 upregulation. Activation of the transcription factor STAT3 by phosphorylation on tyrosine 705 is able to regulate BACE1 expression in neurons. Immunoblot analysis of pSTAT3Tyr705/STAT3 ratio revealed a statistically significant increase (+ 43%) in LPS-treated WT mice versus saline-injected mice (Figure 4C). It is worth noting that such increase was no longer observed after PKR down regulation.

PKR inhibition prevents hippocampal hypometabolism after LPS systemic challenge. Motion matrix from the CT to the MR was applied to the PET scan (automatically coregistered to the CT scan) (Figure 5A). Volumes of interest were retrieved on the PET scan (Figure 5B) and semi-quantification of regional radiotracer uptake, expressed as a percentage of Injected Dose/g, was normalised to the cerebellar uptake. An average was calculated and
the region was then considered as striata. The regional tracer uptake normalized the cerebellar one, was averaged among the mice within each group. We reported in Figure 5 the impairment of metabolism in a subregion of the hippocampus, the Ammon’s horn.

In this specific region, the LPS-WT animals had a statistically significant metabolic drop when compared to the controls. However, in the PKR-/- mice, the metabolism of the Ammon’s horn did not differ whether the mice were under LPS treatment or not (Figure 5C).

**Discussion**

Our results show that systemic inflammation produced by LPS administration can induce neuroinflammation and increased brain Aβ production in wild-type mice. In addition, the genetic invalidation of the kinase PKR in PKR+ mice leads to the reduction of neuroinflammation and Aβ accumulation in these mice treated with systemic LPS. Although in this model phosphorylated tau was not modified in LPS treated mice as compared to non-treated mice, activated GSK3β, and activated STAT3 were increased in LPS treated mice. PKR down regulation has prevented the increased brain levels of these enzymes in LPS injected mice. Several questions are to be addressed.

Firstly, is there a modification of peripheral inflammation in PKR-/- mice underpinning the reduction of neuroinflammation detected in PKR-/- mice treated with repeated LPS administration? An answer may be found by further assessing mRNA levels of TNF-α or other cytokines (IL-1β, IL-6…) in the spleen or liver of wild-type and PKR-/- injected animals.

A second question is how can PKR control brain inflammation? Previous studies have shown that LPS injection induces the activation of the innate immune system with production of blood cytokines such as TNF-α and IL-1β that are able to enter the brain in regions with weak blood brain barrier or by active transport through the endothelium among several mechanisms. Consequently, cytokines can activate microglial cells that can also release local cytokines and can induce a spreading of neuroinflammation. PKR has been shown to participate in the production of inflammatory signals either by
directly activating IKKβ and the NF-κB signaling or by partially controlling the inflammasome. In our study, TNFα is decreased in injected PKR-/- brain as compared to WT mice suggesting that the invalidation of PKR has reduced the ability of microglial cells to synthesize inflammatory cytokines and transfer neuro-inflammatory signals. This effect is also revealed in the hippocampus by the reduction of activated microglial cells in LPS-injected PKR-/- mice as compared to LPS-injected WT mice. The result showing that brain PKR is activated in LPS-injected WT mice as compared to control mice validate this model of neuroinflammation and strengthen the putative role of PKR signaling in the control of cytokines release and microglial activation.

An additional question is how PKR can control Aβ production in this model? Previous reports have revealed that systemic LPS administration can increase Aβ levels in the brain of injected mice. Our results have confirmed these results in wild-type mice but have also found that PKR genetic invalidation partially prevented brain Aβ accumulation in PKR-/- mice. It is not known if this event is linked to increased Aβ production or reduced Aβ degradation but Aβ accumulation is associated with a clear modification of BACE1 protein levels that could lead to increased Aβ production. There are at least two mechanisms that could link BACE1 and PKR activation. The first one is associated with the peculiar upstream open reading frame of BACE1, which leads to an increased mRNA expression under the control of eIF2α23,24. Surprisingly, 24 hours after the last LPS administration, eIF2α phosphorylation was not found augmented in WT mice whereas phosphorylated PKR was increased. This could be due to the specific activation of eIF2α phosphatases one day after the last LPS injection. As opposed to what previous authors have observed, a recent paper has shown that inhibition of eIF2α phosphorylation did not alter BACE1 levels and Aβ production in neuronal cultures or in transgenic mice25. This finding argues in favor of a PKR-dependent and eIF2α-independent mechanism controlling BACE1 levels in neurons. The second mechanism is associated with the control of BACE1 mRNA synthesis by STAT326. Our results have revealed that brain activated STAT3 levels are increased in LPS-injected wild-type mice and not in LPS-injected PKR-/- mice. A previous data has shown that PKR can control the activation of STAT3 and the triggering of the

Figure 2 | Microglial activation in WT and PKR-/- mice hippocampus. Double-labeling in immunofluorescence of DAPI (blue) and IBA1 (red) in hippocampus sagittal sections of WT and PKR-/- mice treated with saline or LPS (A). Relative IOD (integrated optical density) of IBA1 immunoreactivity in activated microglial cells. LPS induces microglial activation in WT mice. PKR inhibition prevents microglial activation after LPS treatment (B). mRNA level of TNF-α evaluated by qRT-PCR and normalized to GAPDH mRNA levels (C). Brain Il-6 levels in controls or after LPS injection in wild type mice and PKR knock-out mice (D). WT [n = 4], PKR-/- [n = 4], *p < 0.05, **p < 0.01, ***p < 0.001.
PKR/STAT3/BACE1 pathway could also explain the features of Aβ accumulation in LPS-treated wild-type and PKR⁻/⁻ mice. Further studies will have to analyze the process of Aβ degradation in this model as well as the putative involvement of γ-secretase in Aβ accumulation.

A last question is why phosphorylated tau is not modified in the brain of LPS-injected mice. A previous study has shown that LPS administration in 3xTg AD mice exacerbates tau phosphorylation at the AT8 antibody site. In our study although we observed a pGSK3-

---

**Figure 3 | Inhibition of PKR decreases BACE1 levels and Aβ production in mice hippocampus after LPS systemic challenge.** Immunoblot analysis (A) and protein levels of mature BACE1 (B) and APP (C) and quantification of Aβ₁₋₄₂ by ELISA (D) in WT and PKR⁻/⁻ mice treated with saline or LPS. LPS induces BACE1 maturation and Aβ production without altering APP levels in WT mice. PKR inhibition prevents BACE1 maturation and Aβ production after LPS treatment. Transcriptional activity on BACE1 in hippocampus assessed with qRT-PCR and normalized to GAPDH mRNA levels (E). Immunoblots (A) have been cropped in this figure. Full length version of BACE1 and APP blots are available in the supplementary Figure 5. WT [n = 4], PKR⁻/⁻ [n = 4], **p < 0.01.
increase in LPS-treated mice which was not associated with increased tau phosphorylation at the AT8 site. As already described for eIF2α phosphorylation, one can suggest that specific phosphatases are activated 24 h after the LPS administration and further studies will be needed to determine the time course of brain tau phosphorylation and dephosphorylation in this model. The process of tau phosphorylation could also differ in the brains of wild-type mice and transgenic mice after LPS injection.

Our [18F]FDG-microPET study revealed that LPS injection in wild-type mice decreases metabolism in the hippocampus (Amon’s Horn) but this effect was not seen in LPS-injected PKR−/− mice. It has been shown previously that sepsis can induce neuroinflammation and a reduction of cerebral metabolism in experimental animals. The authors have demonstrated that in LPS-treated rats, cerebral glucose uptake was reduced in cortical areas and not in the hippocampus but animals received a single LPS injection. The fact that PKR genetic down regulation prevents the modification of neuronal metabolism could be due to the reduced brain neuroinflammation, to the reduction of the observed Aβ accumulation or to the inhibition of pro-apoptotic pathway associated with PKR activation although cleaved PARP levels, indicative of caspase 3 activation, were not modified in LPS-injected wild-type mice.

There are some limitations in our study. All the assessments were performed only at a single time point, 24 hours after the last LPS injection. Further studies will have to decipher if a recovery phase is observed one or two weeks after the induced systemic inflammation either concerning neuroinflammation or Aβ accumulation. Since LPS induces a sickness syndrome, it is difficult to properly assess behavioral disturbances at the time point of our study but cognitive tests could be performed in the future during the recovery phase after LPS administration. Finally the use of new and specific PKR inhibitors in the future will be needed to determine if these results can be reproduced using a pharmacological approach.
Previous studies have shown that systemic infections can exacerbate the evolution of AD patients. In this experimental study, we have shown that systemic inflammation can lead to brain PKR activation and Aβ accumulation (Figure 6). In addition, phosphorylated PKR is increased in the brains and CSF of AD or mild cognitive impairment (MCI)-due to AD patients and CSF PKR levels could correlate with cognitive decline. The reason for increased levels of PKR in AD brain is not known but could be associated with cytokine release or Aβ toxicity and also could be exacerbated by systemic infections or inflammation. An earlier data has revealed that PKR activation could negatively control memory formation in experimental animals.

All these findings argue for an early neuroinflammatory process in AD which could be secondarily driven by systemic inflammation and underline the fact that PKR could be a valid new therapeutic target to reduce neuroinflammation and AD brain lesions, to afford neuroprotection and improve memory in affected individuals.

**Methods**

**Animals.** All experimental protocols used in this study were approved by the Animal Experimentation Committee of the INSERM Institut du Fer à Moulin (UMR-S839) and were performed in accordance with the guidelines of the French Agriculture and Forestry Ministry for handling animals (decrees 87/849, license A75-05-22. C57BL/6j wild type (WT) and PKR knockout (PKR−/−) mice (male, 10 weeks old) were used for all experiments. WT mice were purchased from Janvier (Le Genest St Isaac, France). PKR−/− mice, generated by disruption of exons 2 and 3 of the PKR gene were provided by Dr RCC Chang, The University of Hong Kong, Li Ka Shing Faculty of Medicine, Department of Anatomy, Laboratory of Neurodegenerative Diseases.

All mice were held in a temperature-controlled room under a 12 hours light/dark cycle and had access to food and water ad libitum. Animal experiments were performed in accordance with the guidelines of the French Agriculture, Food and Forestry Ministry for handling animals (decrees 87/849, license A75-05-22).

Mice received daily intraperitoneal (i.p) injections of either saline or LPS from *Escherichia coli* (96 C, 5% mercaptoethanol with 150 g/L SDS. 0.3 M Tris-HCl pH 6.8, 25% glycerol and bromophenol blue), protein samples (25 to 50 μg) were separated on Tris-glycine polyacrylamide gels (normalized to GAPDH) using the previously described deltaCp method.

**Immunostaining.** After fixation in 4% paraformaldehyde, brains were sectioned using a cryostat. Sagittal sections (10 μm) were thaw-mounted on glass slides, dehydrated through graded ethanol, and then cleared in xylene. Slides were covered with DPX mounting medium and sealed.

**Immunohistochemistry.** For immunohistochemistry, sections were incubated in 30% sucrose, frozen in Jung tissue medium (Leica, Nanterre, France) and at room temperature for 2 h with secondary antibodies donkey anti-rabbit IgG (Thermo Scientific), rabbit anti-pTau (Thermo Scientific), rabbit anti-pSTAT3 (Cell Signaling), rabbit anti-Tau (Thermo Scientific), rabbit anti-actin (Sigma, St Louis, MO) and mouse anti-tubulin (Santa Cruz, Banter, France). Sections were rinsed, blocked, and incubated in primary antibodies. Rabbit anti-BACE1 (Rockland Immunochemical Inc., Gilbertsville, PA, USA) and mouse anti-pPKR Thr446 (Abcam, Cambridge, UK) and at room temperature for 2 h with secondary antibodies donkey anti-rabbit Cy3 (Jackson Laboratory, Bar Harbor, Maine, USA). GAPDH primers [forward 5′-GGTCTGGGCCATAGAACTGA-3′ and reverse 5′-CTCGTCCTTCTGGACCAAAAG-3′], TNFα primers [forward 5′-CTTCCTACATCTGCCTGTGG-3′ and reverse 5′-GGCTGTTGGCATAGAAGCTA-3′] and GAPDH primers [forward 5′-AGCTTGGCATACCAAGGAAG-3′ and reverse 5′-TTTGATGTTAGTGGGGTCTCG-3′] were used. cDNA amplification was carried out as follows: denaturation at 95°C for 10 seconds, followed by 45 cycles of denaturation at 95°C for 10 seconds and primer annealing-extension step at 60°C for 30 seconds, ending with a cooling step at 37°C for 30 seconds. All assays were performed in triplicates. Relative levels and gene copy numbers were calculated (normalized to GAPDH) using the previously described deltaCt method.

**In vivo imaging.** Eleven C57BL/6j wild type (WT) and nine PKR knockout (PKR−/−) mice were taken to imaging facility the night before imaging and kept at room temperature with free access to food and water up to 6 hours prior to radiotracer
injection when food was no longer accessible. Positron emission tomography scans were performed in a microPET (Inveon, Siemens). A bolus injection of $^{18}$F-FDG (13+/-1.5 MBq; 150 µl in volume) was administered intraperitoneally while the animal was conscious. After injection, the mouse was returned to its cage to allow for biodistribution for approximately 45 min. Then, the mouse was anesthetized with isoflurane (5% for induction and 1.5% for maintenance at a flow rate of 1 L/min) with a nose cone and placed in a prone position on the platform of the scanner. With the help of a laser alignment device attached to the scanner, the mouse was positioned so that the center of the field corresponded to the brain. A CT scan (80 KV and 500 mA) was run right before the mouse moved into the PET field of view. PET scanning was initiated at 60 min after radiotracer injection. Total scanning duration was 15 min. For co-registration purposes, a 7 T T2-weighted magnetic resonance imaging (C57BL/6) brain scan was used to improve cerebral regional delineation on brain PET imaging. Data from the scanner were formatted into 3 frames, 2D-OSEM reconstructed and corrected for scatter and attenuation. Counts detected by the scanner were converted into MBq/ml by use of Inveon Research Workbench software version 3.0 (Siemens). This software enables multimodality imaging coregistration and allows manual drawing of volumes of interest (Vols). MR spatial resolution allows a rather precise identification of several cerebral regions so we drew on the hippocampus on both hemispheres, as shown on the figure 5b. A background Vol was also drawn outside the mouse body. MR whole brain scan was manually coregistered to the CT-scan.

**Statistical Analysis.** All experiments were performed independently at least three times. All data were normalized and analyzed using the StatView software (Fujitsu). The paired sign test or Student’s t-test was used to compare the experimental and control groups. Results were considered significant for a p < 0.05 using the student test.

1. Duyckaerts, C., Delatour, B. & Potier, M.C. Classification and basic pathology of Alzheimer disease. *Acta Neuropathol* 118, 3–8 (2009).
2. Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer’s disease: progress 20. Yim, H. C. & Williams, B. R. Protein kinase R and the inflammasome. 19. Bonnet, M. C., Daurat, C., Ottone, C. & Meurs, E. F. The N-terminus of PKR is essential for cell death in response to double-stranded RNA.
3. Perry, V. H., Nicoll, J. A. & Holmes, C. Microglia in neurodegenerative disease. 1. Duyckaerts, C, Delatour, B. & Potier, M. C. Classification and basic pathology of Alzheimer disease. 2. Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer’s disease: progress 20. Yim, H. C. & Williams, B. R. Protein kinase R and the inflammasome. 19. Bonnet, M. C., Daurat, C., Ottone, C. & Meurs, E. F. The N-terminus of PKR is essential for cell death in response to double-stranded RNA.

**Acknowledgements.** This work was partially supported by ANR-MAIZ, by INSERM, and APHP. The authors thank Martino Taga, Laetitia Trottier, Carmen Luk, Aude Murerecel, Nicolas Darieux and Florent Auger for their technical help. The authors would also like to thank Drs. Jean Antoine Girault and Anne Roumier from Institut du Fer à Moulin, Paris, for constructive discussion about neuroinflammation in animal models.

**Author contributions.** A.-S.R., F.M.-L. and J.H. designed and performed the study, analyzed the data and wrote the paper. A.-S.R. and F.M.-L. performed the animal experiments and the immunohistochemistry experiments. S.L. and F.M.-L. analyzed the immunohistochemistry data imaging software. C.P., S.G. and E.S. performed and quantified the immunoblot experiments. M.T. contributed to cytokines Elisa analysis. I.R. performed and analyzed the PET imaging studies and contributed to writing and editing. S.M.-S. performed the real-time PCR testing of hippocampus samples. C.Paq. and R.C. contributed to the experimental design and data analysis. B.R. provided the PKR– mice from Hong Kong University.

**Additional information.** Supplementary information accompanies this paper at http://www.nature.com/scientificreports

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Carret-Rebillat, A.-S. & et al. Neuroinflammation and Ab Accumulation Linked To Systemic Inflammation Are Decreased By Genetic PKR Down-Regulation. *Sci. Rep.* 5, 8489; DOI:10.1038/srep08489 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/